APA press release — HIV prevention measures must include behavioral strategies to work: Truvada alone not sufficient

APA urged the inclusion of behavior in all HIV prevention and treatment

On Thursday, May 10, a Food and Drug Administration (FDA) panel recommended approval of the drug Truvada to prevent HIV infection. Truvada is currently used as part of a cocktail of drugs to treat patients with HIV. This FDA recommendation could dramatically expand the use of Truvada to include healthy people who are at risk for contracting HIV.  

In response to this panel’s recommendation and subsequent press coverage, APA released a press statement on Monday, May 14, emphasizing that HIV prevention and treatment measures must include both medical and behavioral strategies to be effective. In February, APA passed a resolution emphasizing the need for prevention research that incorporates strategies to deal with mental health, and substance abuse issues, behavior change and adherence. Titled “Combination Biomedical and Behavioral Approaches to Optimize HIV Prevention (PDF, 83KB),” the resolution calls upon Congress, the executive branch and other governmental and nongovernmental agencies to increase support for further research to identify and disseminate effective strategies to prevent and treat HIV and other sexually transmitted infections.